Author:
Almasri Ihab M.,Taha Mutasem O.,Mohammad Mohammad K.
Publisher
Springer Science and Business Media LLC
Subject
Organic Chemistry,Drug Discovery,Molecular Medicine
Reference36 articles.
1. Ahmad, S., L. Wang, and P.E. Ward. 1992. Dipeptidyl(amino)peptidase IV and aminopeptidase M metabolize circulating substance P in vivo. Journal of Pharmacology and Experimental Therapeutics 260: 1257–1261.
2. Ahren, B., M. Landin-Olsson, P. Jansson, M. Svensson, D. Holmes, and A. Schweizer. 2004. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 89: 2078–2084.
3. Al-masri, I., M. Mohammad, and M. Taha. 2008. Discovery of New DPP IV Inhibitors via pharmacophore Modeling and QSAR Analysis followed by in silico screening. ChemMedChem 3: 1763–1779.
4. Augeri, D.J., J.A. Robl, D.A. Betebenner, D.R. Magnin, A. Khanna, J.G. Robertson, A. Wang, L.M. Simpkins, P. Taunk, Q. Huang, S.-P. Han, B. Abboa-Offei, M. Cap, L. Xin, L. Tao, E. Tozzo, G.E. Welzel, D.M. Egan, J. Marcinkeviciene, S.Y. Chang, S.A. Biller, M.S. Kirby, R.A. Parker, and L.G. Hamann. 2005. Discovery and preclinical profile of saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Journal of Medicinal Chemistry 48: 5025–5037.
5. Barnett, A. 2006. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. International Journal of Clinical Practice 60: 1454–1470.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献